We are actively responding to the global COVID-19 pandemic. For more, please visit our COVID-19 response page, or call 1-877-436-3683. See the latest update on Actemra® (tocilizumab) supply here.

Ayse Meric Ovacik - Principal Scientist Development, Preclinical Translational Pharmacokinetics, Department of Development Sciences

Ayse Meric Ovacik

Principal Scientist Development, Preclinical Translational Pharmacokinetics, Department of Development Sciences

"Genentech is Disneyland for scientists."
7
Years at Genentech
6
Publications at Genentech

I joined Genentech in November 2015 as scientist in the Department of Preclinical Translational Pharmacokinetics (PTPK).

Our department contributes to antibody based drug development from very early stages such as target validation, molecule design and lead selection to lead optimization and first-in-human dose strategies. I represent PTPK in cancer immunotherapy (CIT) programs and support the pipeline for better therapeutic options for the patients in need.